In line with this idea, only a subset of BC patients undergoing anti-PD-1 therapy exhibited an increased frequency of CTLs expressing HLA-DR in their blood (Supplementary Figure S10A) along with elevated HLA-DR expression levels on CTLs (Supplementary Figure S10B), four months after treatment initiation. This evidence concerns the gene PDCD1 and breast cancer.